H. Miles Prince

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients with diffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients with diffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients with diffuse large B-cell lymphoma (DLBLC) prospectively identifies a...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure (2007)

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Primary cutaneous CD4/CD56hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases (2006)

Ng, Dr. Ashley P., Lade, Dr. Stephen, Rutherford, Dr. Timothy, McCormack, Dr. Christopher, Prince, Dr. H. Miles, Westerman, Dr. David

CD4/CD56hematodermic neoplasm (WHO- EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+CD56+lin- skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present...

Primary cutaneous CD4/CD56hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases (2006)

Ng, Dr. Ashley P., Lade, Dr. Stephen, Rutherford, Dr. Timothy, McCormack, Dr. Christopher, Prince, Dr. H. Miles, Westerman, Dr. David

CD4/CD56hematodermic neoplasm (WHO- EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+CD56+lin- skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present...

Primary cutaneous CD4/CD56hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases (2006)

Ng, Dr. Ashley P., Lade, Dr. Stephen, Rutherford, Dr. Timothy, McCormack, Dr. Christopher, Prince, Dr. H. Miles, Westerman, Dr. David

CD4/CD56hematodermic neoplasm (WHO- EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+CD56+lin- skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present...

Primary cutaneous CD4/CD56hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases (2006)

Ng, Dr. Ashley P., Lade, Dr. Stephen, Rutherford, Dr. Timothy, McCormack, Dr. Christopher, Prince, Dr. H. Miles, Westerman, Dr. David

CD4/CD56hematodermic neoplasm (WHO- EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+CD56+lin- skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present...

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy (2006)

Lane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, ...

Pegfilgrastim (Neulasta®) has proven efficacy as supportive therapy in a variety of 21-day chemotherapy regimens, but has not been studied in dose intensive, rapidly cycling regimens utilising...

Primary cutaneous CD4/CD56hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases (2006)

Ng, Dr. Ashley P., Lade, Dr. Stephen, Rutherford, Dr. Timothy, McCormack, Dr. Christopher, Prince, Dr. H. Miles, Westerman, Dr. David

CD4/CD56hematodermic neoplasm (WHO- EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+CD56+lin- skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present...

Primary cutaneous CD4/CD56hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases (2006)

Ng, Dr. Ashley P., Lade, Dr. Stephen, Rutherford, Dr. Timothy, McCormack, Dr. Christopher, Prince, Dr. H. Miles, Westerman, Dr. David

CD4/CD56hematodermic neoplasm (WHO- EORTC) or blastic NK-cell lymphoma (WHO) is a rare aggressive CD4+CD56+lin- skin-tropic lymphoma of putative early-plasmacytoid dendritic cell origin. We present...

Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas (2005)

Nath, Shriram V, Prince, H Miles, Choong, Peter FM, Toner, Guy C

Abstract Background The role of high dose therapy (HDT) with autologous stem cell transplantation (AuSCT) for the treatment of bone and soft tissue sarcomas remains investigational. There are few...

Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas

Nath, Shriram V, Prince, H Miles, Choong, Peter FM, Toner, Guy C

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice

Westwood, Jennifer A., Smyth, Mark J., Teng, Michele W. L., Moeller, Maria, Trapani, Joseph A., Scott, Andrew M., ...

In this study, human T cells were provided with a reactivity against the Lewis-Y (LeY) carbohydrate antigen, which is overexpressed on 70% of epithelial-derived tumors, but not normally recognized by...

Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas

Nath, Shriram V, Prince, H Miles, Choong, Peter FM, Toner, Guy C

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice

Westwood, Jennifer A., Smyth, Mark J., Teng, Michele W. L., Moeller, Maria, Trapani, Joseph A., Scott, Andrew M., ...

In this study, human T cells were provided with a reactivity against the Lewis-Y (LeY) carbohydrate antigen, which is overexpressed on 70% of epithelial-derived tumors, but not normally recognized by...

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

Prince, H Miles, Adena, Michael, Smith, Dell Kingsford, Hertel, Judy

Early therapeutic response assessment by 18FDG-positron emissiontomography during chemotherapy in patients with diffuse large B-celllymphoma: Isolated residual positivity involving bone is not usually apredictor of subsequent treatment failure

Ng, Dr. Ashley P., Wirth, Dr. Andrew, Seymour, Dr. John, Lee, Dr. Michael, Hogg, Dr. Annette, Januszewicz, Dr. Henry, ...

Residual 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography (PET) positivity during treatment of patients withdiffuse large B-cell lymphoma (DLBLC) prospectively identifies a subgroup at...

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

Ritchie, David, Piekarz, Richard L., Blombery, Piers, Karai, Laszlo J., Pittaluga, Stefania, Jaffe, Elaine S., ...

Histone deacetylase inhibitors are a class of anti-cancer agents that induce growth arrest, differentiation, and apoptotic cell death of transformed cells. The authors report three instances of DNA...